NCT03945110View on ClinicalTrials.gov

Intravesical Glycosaminoglycan Instillation and Urinary Tract Infection in Acute Spinal Cord Injury

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 18, 2019

Primary Completion Date

September 22, 2020

Study Completion Date

March 18, 2021

Conditions
Spinal Cord Injuries
Interventions
DEVICE

iAluRil® intravesical instillations

50ml of a sterile solution of sodium hyaluronate (1.6% 800mg/50ml) and sodium chondroitin sulphate (2% - 1 g/50ml) is administered intravesically (directly into the bladder) via a pre-filled syringe connected to a catheter and held in the bladder for at least 30 minutes.

Trial Locations (1)

6000

Royal Perth Hospital, Perth

All Listed Sponsors
collaborator

Royal Perth Hospital

OTHER

collaborator

Fiona Stanley Hospital

OTHER

collaborator

Perth Urology Clinic

UNKNOWN

lead

The University of Western Australia

OTHER

NCT03945110 - Intravesical Glycosaminoglycan Instillation and Urinary Tract Infection in Acute Spinal Cord Injury | Biotech Hunter | Biotech Hunter